



Table S1. All selected features for our radiomics signature.

Feature	MRI	VOI
	sequence	
Malignant vs. benign lesions		
'original_firstorder_Median'	ADC	lesion
'original_glrlm_RunLengthNonUniformity'	T2	wholegland
'original_shape_Flatness'	T2	whole gland
'original_glrlm_ShortRunLowGrayLevelEmphasis'	T2	whole gland
'original_shape_Sphericity'	T2	whole gland
'original_firstorder_Variance'	ADC	lesion
'original_shape_Flatness'	T2	lesion
'original_firstorder_10Percentile'	ADC	lesion
'original_shape_Maximum2DDiameterRow'	T2	whole gland
'original_firstorder_Energy'	ADC	lesion
'original_firstorder_Skewness'	ADC	lesion
'original_shape_Elongation'	T2	whole gland
'original_firstorder_Maximum'	ADC	lesion
'original_glrlm_LongRunEmphasis'	T2	whole gland
'original_shape_Elongation'	ADC	lesion
csPCa vs. cisPCa		
'original_shape_Maximum2DDiameterColumn'	T2	whole gland
'original_firstorder_Maximum'	ADC	lesion
'original_shape_Sphericity'	T2	whole gland
'original_glrlm_GrayLevelNonUniformityNormalized'	T2	lesion
'original_shape_Elongation'	ADC	lesion
'original_glrlm_LongRunHighGrayLevelEmphasis'	T2	lesion
'original_firstorder_Median'	ADC	lesion
'original_glrlm_ShortRunLowGrayLevelEmphasis'	T2	whole gland
'original_shape_Elongation'	T2	whole gland
'original_shape_Sphericity'	ADC	lesion
'original_firstorder_Skewness'	ADC	lesion
'original_glrlm_RunEntropy'	T2	whole gland
'original_shape_SurfaceVolumeRatio'	T2	whole gland
'original_shape_Flatness'	T2	lesionv
'original_firstorder_Kurtosis'	ADC	lesion

Cancers 2020, 12, 1767 2 of 4

Table S2. Zonal subgroup analysis of the diagnostic performance of the radiomics model, PI-RADS and mADC.

Predictor	AUC ROC	95% CI	P value*	Sensitivity (%)•	95% CI (%)	P value†	Specificity (%)•	95% CI (%)
	malignant vs. benign lesions							
Peripheral zone				-				
PI-RADS	0.781	[0.694-0.856]	0.469	73 (38/52)	[60-85]	0.301	71 (35/49)	[58-84]
mADC	0.820	[0.730-0.898]	0.901	71 (37/52)	[58-83]	0.109	82 (40/49)	[80-92]
Radiomics model	0.824	[0.731-0.902]	ref.	83 (43/52)	[71-92]	ref.	75 (37/49)	[63-86]
Transition zone								
PI-RADS	0.683	[0.544-0.816]	0.979	63 (12/19)	[42-84]	0.453	70 (21/30)	[52-86]
mADC	0.601	[0.434-0.761]	0.302	63 (12/19)	[42-84]	0.25	60 (18/30)	[41-78]
Radiomics model	0.683	[0.544-0.817]	ref.	47 (9/19)	[25-70]	ref.	70 (21/30)	[52-86]
	csPCa vs. cisPCa							
Peripheral zone								
PI-RADS	0.660	[0.472-0.873]	0.040	80 (33/41)	[67-92]	0.581	54 (6/11)	[25-83]
mADC	0.809	[0.637-0.930]	0.284	76 (31/41)	[62-88]	0.125	73 (8/11)	[44-100]
Radiomics model	0.894	[0.801-0.971]	ref.	88 (36/41)	[76-97]	ref.	64 (7/11)	[33-91]
Transition zone								
PI-RADS	0.700	[0.371-0.910]	0.329	77 (10/13)	[53-100]	1.0	66 (4/6)	[25-100]
mADC	0.397	[0.092-0.641]	0.388	54 (7/13)	[29-82]	0.688	33 (2/6)	[0-75]
Radiomics model	0.587	[0.275-0.857]	ref.	69 (9/13)	[42-92]	ref.	67 (4/6)	[25-100]

^{*}DeLong test for differences in AUC ROC compared with the reference

 Table S3. Multiparametric prostate MRI protocol.

MRI sequences	Orientation	TE (ms)	TR (ms)	Slice thickness (mm)	FoV read (mm)	
MRI scanner no. 1 (Siemens, Magnetom Trio, 3T)						
DWI b50/500/800	tra	88	5000	3	204	
t2_haste_sag	sag	105	1200	4	281*300	
t2_tse_cor	cor	101	4000	3	200	
t2_tse_tra	tra	101	4580	3	200	
t2_tse_sag	sag	101	4190	3	200	
t1_vibe_cor_iso	cor	2.15	4.71	0.91	290	
t1_tse_tra	tra	9.8	858	3	200	
	MRI scanne	r no. 2 (Siem	ens, Magnet	om Skyra, 3T)		
DCE (Grasp)	tra	1.69	3.85	1.5	240	
DWI zoomit_epi	tra	69	3800	3	380	
DWI zoomit_epi_2000	tra	91	4600	3	380	
t1_twist_tra	tra	1.97	5.05	3.5	260	
t2_tse_tra	tra	104	3300	3	200	
t2_tse_sag	sag	104	3600	3	200	
t2_tse_cor	cor	104	3200	3	200	
DWI ep2d_dif	tra	69	3600	4	200	

[°]in brackets proportion of raw data

[†]McNemar test for differences in sensitivity compared with reference.

Cancers **2020**, 12, 1767

Table S4. Radiomic feature classes used for each setup.

Feature setup	Classes extracted from lesion VOI	Classes extracted from whole prostate VOI
	Shape	Shape
	first order	first order
All features	GLRLM	GLRLM
	GLSZM	GLSZM
	GLDM	GLDM
	shape:	shape:
	'VoxelVolume'	'VoxelVolume'
	'SurfaceVolumeRatio'	'Maximum2DDiameterSlice'
	'Maximum2DDiameterRow'	'Maximum3DDiameter'
	first order:	'Maximum2DDiameterColumn'
	'Range'	first order:
	'Minimum'	'Variance'
	'90Percentile'	'RobustMeanAbsoluteDeviation'
	'Mean'	'10Percentile'
Features from	GLRLM:	GLRLM:
	'RunLengthNonUniformity'	'RunPercentage'
Schwier et al. [1]	'HighGrayLevelRunEmphasis'	'RunLengthNonUniformityNormalized'
	'ShortRunHighGrayLevelEmphasis'	'GrayLevelVariance'
	GLSZM:	GLSZM:
	'SmallAreaHighGrayLevelEmphasis'	'ZoneEntropy'
	'SizeZoneNonUniformityNormalized'	'SmallAreaEmphasis'
	'HighGrayLevelZoneEmphasis'	'SizeZoneNonUniformityNormalized'
	GLCM:	GLCM:
	'DifferenceAverage'	'JointEnergy'
	'Contrast'	'Imc1'
	'Autocorrelation'	'Correlation'
	shape	shape
Radiologist	first order	first order
suggestion	GLRLM	GLRLM

Table S5. Model selection on the training set.

	T	mean AUC ROC (100 repeats 5-fold CV)		
Model	Feature setup*	malignant vs. benign	csPCa vs. cisPCa	
Radiomics:				
	All	0.785	0.721	
Logistic Regression	Custom	0.800	0.786	
	VOI	0.796	0.638	
	All	0.783	0.738	
SVM	Custom	0.799	0.814	
	VOI	0.783	0.660	
	All	0.798	0.646	
Random Forest	Custom	0.804	0.657	
	VOI	0.779	0.570	
	All	0.797	0.594	
XGBoost	Custom	0.793	0.624	
	VOI	0.747	0.572	
Deep learning:				
EfficientNet	-	0.702	0.657	
XMasNet	_	0.712	0.674	

^{*}Feature setup abbreviations: *All* - all features, *VOI* - features suggested by Schwier et al., *Custom* - radiologist suggestion

Cancers 2020, 12, 1767 4 of 4

Reference

1. Schwier, M.; Griethuysen, J. V.; Vangel, M. G.; Pieper, S.; Peled, S.; Tempany, C.; Aerts, H. J. W. L.; Kikinis, R.; Fennessy, F. M.; Fedorov, A. Repeatability of Multiparametric Prostate MRI Radiomics Features. *Sci. Rep.* **2019**, *9*, 1–6.